Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 1.00 |
| ▸ | CES1 | P23141 | 2/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.76 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.76 |
| ▸ | F3 | P13726 | 1/20 | 0.76 |
| ▸ | PNLIP | P16233 | 1/20 | 0.76 |
| ▸ | NOS2 | P35228 | 1/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.66 |
| ▸ | RELA | Q04206 | 3/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2453965 | 1.00 | CES2 (1.00) | CES2CES1PTPN1PTPN2F3 | |
| SCHEMBL12313092 | 1.00 | CES2 (1.00) | CES2CES1PTPN1PTPN2F3 | |
| SCHEMBL18687839 | 1.00 | CES2 (1.00) | CES2CES1PTPN1PTPN2F3 | |
| SCHEMBL14240644 | 0.89 | CES2 (0.80) | CES2CES1PTPN1PTPN2F3 | |
| SCHEMBL14226153 | 0.89 | CES2 (0.80) | CES2CES1PTPN1PTPN2F3 | |
| SCHEMBL8895640 | 0.88 | CES2 (1.00) | CES2CES1PTPN1PTPN2F3 | |
| SCHEMBL2592927 | 0.88 | CES2 (1.00) | CES2CES1PTPN1PTPN2F3 | |
| SCHEMBL20511990 | 0.88 | CES2 (1.00) | CES2CES1PTPN1PTPN2F3 | |
| SCHEMBL38653836 | 0.88 | CES2 (0.78) | CES2CES1PTPN1PTPN2F3 | |
| SCHEMBL8895636 | 0.88 | CES2 (1.00) | CES2CES1PTPN1PTPN2F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731172-A2 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE NATURAL RESIN AND A CRYSTALLIZABLE FATTY SUBSTANCE | L'OREAL (FR) | 2026-04-29 | — | — | EP | claimed |
| EP-4551300-A1 | COSMETIC COMPOSITION COMPRISING A NATURAL RESIN | L'OREAL (FR) | 2025-05-14 | — | — | EP | claimed |
| US-20250064716-A1 | COSMETIC COMPOSITION COMPRISING A NATURAL RESIN | L'OREAL (FR) | 2025-02-27 | — | — | US | claimed |
| WO-2024261287-A2 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE NATURAL RESIN AND A CRYSTALLIZABLE FATTY SUBSTANCE | L'OREAL (FR) | 2024-12-26 | — | — | WO | claimed |
| EP-4452200-A1 | COSMETIC COMPOSITION COMPRISING A NATURAL RESIN | L'OREAL (FR) | 2024-10-30 | — | — | EP | claimed |
| WO-2024008771-A1 | COSMETIC COMPOSITION COMPRISING A NATURAL RESIN | L'OREAL (FR) | 2024-01-11 | — | — | WO | claimed |
| WO-2024008772-A1 | COSMETIC COMPOSITION COMPRISING A NATURAL RESIN | L'OREAL (FR) | 2024-01-11 | — | — | WO | claimed |
| WO-2024008769-A1 | COSMETIC COMPOSITION COMPRISING A NATURAL RESIN | L'OREAL (FR) | 2024-01-11 | — | — | WO | claimed |
| WO-2023118430-A1 | COSMETIC COMPOSITION COMPRISING A NATURAL RESIN | L'OREAL (FR) | 2023-06-29 | — | — | WO | claimed |
| US-20250213441-A1 | Cosmetic Composition Comprising a Natural Resin | L'OREAL (FR) | 2025-07-03 | — | — | US | disclosed |
| CN-119868373-B | Application of small molecular compound in ischemic heart disease | 四川省医学科学院·四川省人民医院 | 2025-06-13 | — | — | CN | disclosed |
| EP-4551184-A1 | LIQUID EMULSION COMPRISING ETHYLCELLULOSE, A NATURAL RESIN, A LIQUID FATTY ALCOHOL, A SOLID ESTER AND/OR A POLAR HYDROCARBON-BASED OIL AND PROCESS USING SAME | L'OREAL (FR) | 2025-05-14 | — | — | EP | disclosed |
| EP-4551300-A1 | COSMETIC COMPOSITION COMPRISING A NATURAL RESIN | L'OREAL (FR) | 2025-05-14 | — | — | EP | disclosed |
| CN-119868373-A | Application of small molecular compound in ischemic heart disease | 四川省医学科学院·四川省人民医院 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024008771-A1 | COSMETIC COMPOSITION COMPRISING A NATURAL RESIN | L'OREAL (FR) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024008772-A1 | COSMETIC COMPOSITION COMPRISING A NATURAL RESIN | L'OREAL (FR) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023118430-A1 | COSMETIC COMPOSITION COMPRISING A NATURAL RESIN | L'OREAL (FR) | 2023-06-29 | — | — | WO | disclosed |
| US-11632946-B2 | Cat deterrent compositions and methods of use of same | SKEDDADER INC. (CA) | 2023-04-25 | — | — | US | disclosed |
| CN-115463128-A | Panipenem betamipron compound combination medicine for injection and preparation method thereof | 深圳太太药业有限公司 | 2022-12-13 | — | — | CN | disclosed |
| WO-2022197576-A1 | PROCESS FOR PREPARING ABSOLUTES | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213441-A1 | Cosmetic Composition Comprising a Natural Resin | KRT18, CUTA, EPCAM | CES2 1178/4885CES1 1455/4885PTPN1 4080/4885 |
| US-20250064716-A1 | COSMETIC COMPOSITION COMPRISING A NATURAL RESIN | KRT18, CUTA, RARA | CES2 1170/4885CES1 1914/4885PTPN1 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.